Robert Wasserman
Stock Analyst at Benchmark
(2.17)
# 2,658
Out of 4,784 analysts
115
Total ratings
39%
Success rate
-4.46%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KMDA Kamada | Initiates: Buy | $15 | $6.75 | +122.22% | 1 | Mar 21, 2025 | |
| OABI OmniAb | Maintains: Buy | $8 → $6 | $2.42 | +147.93% | 8 | Mar 20, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $2.31 | - | 6 | Mar 3, 2025 | |
| ITGR Integer Holdings | Maintains: Buy | $140 → $150 | $116.95 | +28.26% | 10 | Feb 21, 2025 | |
| HALO Halozyme Therapeutics | Reiterates: Buy | $75 | $63.84 | +17.48% | 8 | Feb 20, 2025 | |
| LGND Ligand Pharmaceuticals | Reiterates: Buy | $135 | $107.62 | +25.44% | 10 | Dec 23, 2024 | |
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $25.96 | +15.56% | 6 | Dec 19, 2024 | |
| ANEB Anebulo Pharmaceuticals | Reiterates: Speculative Buy | $8 | $1.36 | +488.24% | 6 | Nov 19, 2024 | |
| NEPH Nephros | Reiterates: Speculative Buy | $5 | $1.67 | +199.40% | 3 | Nov 12, 2024 | |
| EBS Emergent BioSolutions | Maintains: Buy | $8 → $12 | $4.66 | +157.51% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.81 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $5 → $3 | $0.39 | +665.31% | 5 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $58.73 | +61.76% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $133.41 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $12 | $1.95 | +515.38% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $35.76 | +25.84% | 6 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $3.44 | +16.28% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.39 | +928.28% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $1.61 | +4,558.39% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $205.85 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $500.16 | +15.96% | 1 | Jul 16, 2021 |
Kamada
Mar 21, 2025
Initiates: Buy
Price Target: $15
Current: $6.75
Upside: +122.22%
OmniAb
Mar 20, 2025
Maintains: Buy
Price Target: $8 → $6
Current: $2.42
Upside: +147.93%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $2.31
Upside: -
Integer Holdings
Feb 21, 2025
Maintains: Buy
Price Target: $140 → $150
Current: $116.95
Upside: +28.26%
Halozyme Therapeutics
Feb 20, 2025
Reiterates: Buy
Price Target: $75
Current: $63.84
Upside: +17.48%
Ligand Pharmaceuticals
Dec 23, 2024
Reiterates: Buy
Price Target: $135
Current: $107.62
Upside: +25.44%
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $25.96
Upside: +15.56%
Anebulo Pharmaceuticals
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $1.36
Upside: +488.24%
Nephros
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $1.67
Upside: +199.40%
Emergent BioSolutions
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $4.66
Upside: +157.51%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.81
Upside: -
Aug 14, 2024
Maintains: Speculative Buy
Price Target: $5 → $3
Current: $0.39
Upside: +665.31%
Aug 13, 2024
Reiterates: Buy
Price Target: $95
Current: $58.73
Upside: +61.76%
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $133.41
Upside: -
Jul 11, 2024
Reiterates: Speculative Buy
Price Target: $12
Current: $1.95
Upside: +515.38%
May 29, 2024
Reiterates: Buy
Price Target: $45
Current: $35.76
Upside: +25.84%
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $3.44
Upside: +16.28%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.39
Upside: +928.28%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $1.61
Upside: +4,558.39%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $205.85
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $500.16
Upside: +15.96%